Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

The role of proteomics in the age of immunotherapies.

Hayes SA, Clarke S, Pavlakis N, Howell VM.

Mamm Genome. 2018 Jul 25. doi: 10.1007/s00335-018-9763-6. [Epub ahead of print] Review.

PMID:
30046851
2.

ROS1-Rearranged Non-Small-Cell Lung Cancer, Factor V Leiden, and Recurrent Venous Thromboses.

Lee A, Howell VM, Itchins M, Wheeler HR, Pavlakis N.

Clin Lung Cancer. 2018 Jun 5. pii: S1525-7304(18)30135-9. doi: 10.1016/j.cllc.2018.05.015. [Epub ahead of print] No abstract available.

PMID:
29945753
3.

Pattern of care and survival of anaplastic lymphoma kinase rearranged non-small cell lung cancer (ALK+ NSCLC) in an Australian Metropolitan Tertiary Referral Centre: A retrospective cohort analysis.

Itchins M, Hayes SA, Gill AJ, Cooper W, O'Connell R, Howell VM, Clarke SJ, Pavlakis N.

Asia Pac J Clin Oncol. 2018 Apr 19. doi: 10.1111/ajco.12877. [Epub ahead of print]

PMID:
29675948
4.

Biodistribution and Clearance of Stable Superparamagnetic Maghemite Iron Oxide Nanoparticles in Mice Following Intraperitoneal Administration.

Pham BTT, Colvin EK, Pham NTH, Kim BJ, Fuller ES, Moon EA, Barbey R, Yuen S, Rickman BH, Bryce NS, Bickley S, Tanudji M, Jones SK, Howell VM, Hawkett BS.

Int J Mol Sci. 2018 Jan 10;19(1). pii: E205. doi: 10.3390/ijms19010205.

5.

Acinar cell density at the pancreatic resection margin is associated with post-pancreatectomy pancreatitis and the development of postoperative pancreatic fistula.

Nahm CB, Brown KM, Townend PJ, Colvin E, Howell VM, Gill AJ, Connor S, Samra JS, Mittal A.

HPB (Oxford). 2018 May;20(5):432-440. doi: 10.1016/j.hpb.2017.11.003. Epub 2018 Jan 5.

PMID:
29307511
6.

Functional prediction of long non-coding RNAs in ovarian cancer-associated fibroblasts indicate a potential role in metastasis.

Vafaee F, Colvin EK, Mok SC, Howell VM, Samimi G.

Sci Rep. 2017 Sep 4;7(1):10374. doi: 10.1038/s41598-017-10869-y.

7.

Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context.

Itchins M, Chia PL, Hayes SA, Howell VM, Gill AJ, Cooper WA, John T, Mitchell P, Millward M, Clarke SJ, Solomon B, Pavlakis N.

Asia Pac J Clin Oncol. 2017 Aug;13 Suppl 3:3-13. doi: 10.1111/ajco.12754. Review.

PMID:
28795492
8.

Exhaled breath condensate for lung cancer protein analysis: a review of methods and biomarkers.

Hayes SA, Haefliger S, Harris B, Pavlakis N, Clarke SJ, Molloy MP, Howell VM.

J Breath Res. 2016 Jul 5;10(3):034001. doi: 10.1088/1752-7155/10/3/034001. Review.

PMID:
27380020
9.

29th International Mammalian Genome Conference meeting report.

Gonzales NM, Howell VM, Smith CM.

Mamm Genome. 2016 Jun;27(5-6):169-78. doi: 10.1007/s00335-016-9640-0. Epub 2016 May 2. Review. No abstract available.

PMID:
27137837
10.

Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma.

Parker NR, Hudson AL, Khong P, Parkinson JF, Dwight T, Ikin RJ, Zhu Y, Cheng ZJ, Vafaee F, Chen J, Wheeler HR, Howell VM.

Sci Rep. 2016 Mar 4;6:22477. doi: 10.1038/srep22477.

11.

The Extracellular Matrix in Epithelial Ovarian Cancer - A Piece of a Puzzle.

Cho A, Howell VM, Colvin EK.

Front Oncol. 2015 Nov 2;5:245. doi: 10.3389/fonc.2015.00245. eCollection 2015. Review.

12.

Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer.

Moran-Jones K, Gloss BS, Murali R, Chang DK, Colvin EK, Jones MD, Yuen S, Howell VM, Brown LM, Wong CW, Spong SM, Scarlett CJ, Hacker NF, Ghosh S, Mok SC, Birrer MJ, Samimi G.

Oncotarget. 2015 Dec 29;6(42):44551-62. doi: 10.18632/oncotarget.6082.

13.

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model.

Weir CJ, Hudson AL, Peters L, Howell VM.

J Vis Exp. 2015 Oct 2;(104). doi: 10.3791/53019.

14.

Editorial: Advances in Epithelial Ovarian Cancer: Model Systems, Microenvironmental Influences, Therapy, and Origins.

Howell VM, Davidson B.

Front Oncol. 2015 Sep 22;5:205. doi: 10.3389/fonc.2015.00205. eCollection 2015. No abstract available.

15.

Granulosa Cell-Specific Brca1 Loss Alone or Combined with Trp53 Haploinsufficiency and Transgenic FSH Expression Fails to Induce Ovarian Tumors.

Upton DH, Fuller ES, Colvin EK, Walters KA, Jimenez M, Desai R, Handelsman DJ, Howell VM, Allan CM.

Horm Cancer. 2015 Aug;6(4):142-52. doi: 10.1007/s12672-015-0222-5. Epub 2015 May 6.

PMID:
25943777
16.

Molecular heterogeneity in glioblastoma: potential clinical implications.

Parker NR, Khong P, Parkinson JF, Howell VM, Wheeler HR.

Front Oncol. 2015 Mar 3;5:55. doi: 10.3389/fonc.2015.00055. eCollection 2015. Review.

17.

Reporting in studies of protein biomarkers of prognosis in colorectal cancer in relation to the REMARK guidelines.

Jankova L, Dent OF, Molloy MP, Chan C, Chapuis PH, Howell VM, Clarke SJ.

Proteomics Clin Appl. 2015 Dec;9(11-12):1078-86. doi: 10.1002/prca.201400177. Epub 2015 May 7.

PMID:
25755195
18.

Genomic alterations as mediators of miRNA dysregulation in ovarian cancer.

Kan CW, Howell VM, Hahn MA, Marsh DJ.

Genes Chromosomes Cancer. 2015 Jan;54(1):1-19. doi: 10.1002/gcc.22221. Epub 2014 Oct 3. Review.

PMID:
25280227
19.

Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma.

Hudson AL, Weir C, Moon E, Harvie R, Klebe S, Clarke SJ, Pavlakis N, Howell VM.

Sci Rep. 2014 Aug 21;4:6152. doi: 10.1038/srep06152.

20.

Genetically engineered insertional mutagenesis in mice to model cancer: Sleeping Beauty.

Howell VM, Colvin EK.

Methods Mol Biol. 2014;1194:367-83. doi: 10.1007/978-1-4939-1215-5_21.

PMID:
25064115
21.

Succinate dehydrogenase subunit D and succinate dehydrogenase subunit B mutation analysis in canine phaeochromocytoma and paraganglioma.

Holt DE, Henthorn P, Howell VM, Robinson BG, Benn DE.

J Comp Pathol. 2014 Jul;151(1):25-34. doi: 10.1016/j.jcpa.2014.03.007. Epub 2014 Mar 27.

PMID:
24813157
22.

Streptavidin: a novel immunostimulant for the selection and delivery of autologous and syngeneic tumor vaccines.

Weir C, Hudson AL, Moon E, Ross A, Alexander M, Peters L, Langova V, Clarke SJ, Pavlakis N, Davey R, Howell VM.

Cancer Immunol Res. 2014 May;2(5):469-79. doi: 10.1158/2326-6066.CIR-13-0157. Epub 2014 Feb 21.

23.

Culture models to define key mediators of cancer matrix remodeling.

Fuller ES, Howell VM.

Front Oncol. 2014 Mar 25;4:57. doi: 10.3389/fonc.2014.00057. eCollection 2014. Review.

24.

From mice to men: GEMMs as trial patients for new NSCLC therapies.

Hayes SA, Hudson AL, Clarke SJ, Molloy MP, Howell VM.

Semin Cell Dev Biol. 2014 Mar;27:118-27. doi: 10.1016/j.semcdb.2014.04.002. Epub 2014 Apr 6. Review.

PMID:
24718320
25.

Mice and men working together for over 100 years in the fight against cancer.

Howell VM.

Semin Cell Dev Biol. 2014 Mar;27:52-3. doi: 10.1016/j.semcdb.2014.04.001. Epub 2014 Apr 3. No abstract available.

PMID:
24704434
26.

Genetically engineered mouse models for epithelial ovarian cancer: are we there yet?

Howell VM.

Semin Cell Dev Biol. 2014 Mar;27:106-17. doi: 10.1016/j.semcdb.2014.03.019. Epub 2014 Mar 29. Review.

PMID:
24685617
27.
28.

Transposon mutagenesis reveals cooperation of ETS family transcription factors with signaling pathways in erythro-megakaryocytic leukemia.

Tang JZ, Carmichael CL, Shi W, Metcalf D, Ng AP, Hyland CD, Jenkins NA, Copeland NG, Howell VM, Zhao ZJ, Smyth GK, Kile BT, Alexander WS.

Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6091-6. doi: 10.1073/pnas.1304234110. Epub 2013 Mar 26.

29.

Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer.

Kan CW, Hahn MA, Gard GB, Maidens J, Huh JY, Marsh DJ, Howell VM.

BMC Cancer. 2012 Dec 28;12:627. doi: 10.1186/1471-2407-12-627.

30.

Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial infarction.

Loan Le TY, Mardini M, Howell VM, Funder JW, Ashton AW, Mihailidou AS.

Hypertension. 2012 Jun;59(6):1164-9. doi: 10.1161/HYPERTENSIONAHA.111.190488. Epub 2012 Apr 16.

PMID:
22508833
31.

Sleeping beauty--a mouse model for all cancers?

Howell VM.

Cancer Lett. 2012 Apr 1;317(1):1-8. doi: 10.1016/j.canlet.2011.11.006. Epub 2011 Nov 10. Review.

PMID:
22079740
32.

The use of denaturing high performance liquid chromatography (DHPLC) for mutation scanning of hereditary cancer genes.

Marsh DJ, Howell VM.

Methods Mol Biol. 2010;653:133-45. doi: 10.1007/978-1-60761-759-4_8. Review.

PMID:
20721741
33.

CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors.

Hahn MA, Howell VM, Gill AJ, Clarkson A, Weaire-Buchanan G, Robinson BG, Delbridge L, Gimm O, Schmitt WD, Teh BT, Marsh DJ.

Endocr Relat Cancer. 2010 Feb 18;17(1):273-82. doi: 10.1677/ERC-09-0291. Print 2010 Mar.

34.

Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma.

Howell VM, Gill A, Clarkson A, Nelson AE, Dunne R, Delbridge LW, Robinson BG, Teh BT, Gimm O, Marsh DJ.

J Clin Endocrinol Metab. 2009 Feb;94(2):434-41. doi: 10.1210/jc.2008-1740. Epub 2008 Nov 18.

PMID:
19017757
35.

A targeted deleterious allele of the splicing factor SCNM1 in the mouse.

Howell VM, de Haan G, Bergren S, Jones JM, Culiat CT, Michaud EJ, Frankel WN, Meisler MH.

Genetics. 2008 Nov;180(3):1419-27. doi: 10.1534/genetics.108.094227. Epub 2008 Sep 14.

36.

Molecular diagnosis of primary hyperparathyroidism in familial cancer syndromes.

Marsh DJ, Hahn MA, Howell VM, Gill AJ.

Expert Opin Med Diagn. 2007 Nov;1(3):377-92. doi: 10.1517/17530059.1.3.377.

PMID:
23489357
37.

Evidence for a direct role of the disease modifier SCNM1 in splicing.

Howell VM, Jones JM, Bergren SK, Li L, Billi AC, Avenarius MR, Meisler MH.

Hum Mol Genet. 2007 Oct 15;16(20):2506-16. Epub 2007 Jul 26.

PMID:
17656373
38.

Rapid mutation screening for HRPT2 and MEN1 mutations associated with familial and sporadic primary hyperparathyroidism.

Howell VM, Cardinal JW, Richardson AL, Gimm O, Robinson BG, Marsh DJ.

J Mol Diagn. 2006 Nov;8(5):559-66.

39.
40.

[Prophylactic parathyroidectomy for familial parathyroid carcinoma].

Gimm O, Lorenz K, Nguyen Thanh P, Schneyer U, Bloching M, Howell VM, Marsh DJ, Teh BT, Krause U, Dralle H.

Chirurg. 2006 Jan;77(1):15-24. German.

PMID:
16418876
41.

Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype.

Haven CJ, Howell VM, Eilers PH, Dunne R, Takahashi M, van Puijenbroek M, Furge K, Kievit J, Tan MH, Fleuren GJ, Robinson BG, Delbridge LW, Philips J, Nelson AE, Krause U, Dralle H, Hoang-Vu C, Gimm O, Morreau H, Marsh DJ, Teh BT.

Cancer Res. 2004 Oct 15;64(20):7405-11.

42.

A molecular diagnosis of hyperparathyroidism-jaw tumor syndrome in an adolescent with recurrent kidney stones.

Howell VM, Zori RT, Stalker HJ, Williams C, Jesse N, Nelson AE, Robinson BG, Marsh DJ.

J Pediatr. 2004 Oct;145(4):567. No abstract available.

PMID:
15480389
43.

Carrier screening for Canavan disease in Australia.

Howell VM, Proos AL, LaRue D, Jensen CH, Beach F, Burnett L.

J Inherit Metab Dis. 2004;27(2):289-90.

PMID:
15243987
44.

Human gene mutations. Gene symbol: HRPT2. Disease: Hyperparathyroidism Jaw-tumor syndrome.

Teh BT, Howell VM, Haven CJ, Kahnoski K, Khoo SK, Petillo D, Chen J, Fleuren GJ, Robinson BG, Delbridge LW, Philips J, Nelson AE, Krause U, Hammje K, Dralle H, Hoang-Vu C, Gimm O, Marsh DJ, Morreau H.

Hum Genet. 2004 Jan;114(2):224. No abstract available.

PMID:
15046109
45.

Human gene mutations. Gene symbol: HRPT2. Disease: Hyperparathyroidism Jaw-tumor syndrome.

Teh BT, Howell VM, Haven CJ, Kahnoski K, Khoo SK, Petillo D, Chen J, Fleuren GJ, Robinson BG, Delbridge LW, Philips J, Nelson AE, Krause U, Hammje K, Dralle H, Hoang-Vu C, Gimm O, Marsh DJ, Morreau H.

Hum Genet. 2004 Jan;114(2):223. No abstract available.

PMID:
15046107
46.

Human gene mutations. Gene symbol: HRPT2. Disease: Hyperparathyroidism Jaw-tumor syndrome.

Teh BT, Howell VM, Haven CJ, Kahnoski K, Khoo SK, Petillo D, Chen J, Fleuren GJ, Robinson BG, Delbridge LW, Philips J, Nelson AE, Krause U, Hammje K, Dralle H, Hoang-Vu C, Gimm O, Marsh DJ, Morreau H.

Hum Genet. 2004 Jan;114(2):223. No abstract available.

PMID:
15046105
47.

Human gene mutations. Gene symbol: HRPT2. Disease: Hyperparathyroidism Jaw-tumor syndrome.

Teh BT, Howell VM, Haven CJ, Kahnoski K, Khoo SK, Petillo D, Chen J, Fleuren GJ, Robinson BG, Delbridge LW, Philips J, Nelson AE, Krause U, Hammje K, Dralle H, Hoang-Vu C, Gimm O, Marsh DJ, Morreau H.

Hum Genet. 2004 Jan;114(2):223. No abstract available.

PMID:
15046102
48.

Human gene mutations. Gene symbol: HRPT2. Disease: Hyperparathyroidism Jaw-tumor syndrome.

Teh BT, Howell VM, Haven CJ, Kahnoski K, Khoo SK, Petillo D, Chen J, Fleuren GJ, Robinson BG, Delbridge LW, Philips J, Nelson AE, Krause U, Hammje K, Dralle H, Hoang-Vu C, Gimm O, Marsh DJ, Morreau H.

Hum Genet. 2004 Jan;114(2):222. No abstract available.

PMID:
15046098
49.

Human gene mutations. Gene symbol: HRPT2. Disease: Hyperparathyroidism Jaw-tumor syndrome.

Teh BT, Howell VM, Haven CJ, Kahnoski K, Khoo SK, Petillo D, Chen J, Fleuren GJ, Robinson BG, Delbridge LW, Philips J, Nelson AE, Krause U, Hammje K, Dralle H, Hoang-Vu C, Gimm O, Marsh DJ, Morreau H.

Hum Genet. 2004 Jan;114(2):222. No abstract available.

PMID:
15046094
50.

Human gene mutations. Gene symbol: HRPT2. Disease: Hyperparathyroidism Jaw-tumor syndrome.

Teh BT, Howell VM, Haven CJ, Kahnoski K, Khoo SK, Petillo D, Chen J, Fleuren GJ, Robinson BG, Delbridge LW, Philips J, Nelson AE, Krause U, Hammje K, Dralle H, Hoang-Vu C, Gimm O, Marsh DJ, Morreau H.

Hum Genet. 2004 Jan;114(2):221. No abstract available.

PMID:
15046050

Supplemental Content

Loading ...
Support Center